Treatment of venous thromboembolic disease.
D000284:Administration, Oral; D000721:Ancrod / Q000627:therapeutic use; D000925:Anticoagulants / Q000494:pharmacology; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D010960:Plasminogen Activators / Q000097:blood; D011247:Pregnancy; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000601:surgery; D013300:Streptokinase / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D014812:Vitamin K; D006493:Heparin; D013300:Streptokinase; D000721:Ancrod; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator